ALYREF and central nervous system cancer: Furthermore, Zhao et al. showed that in glioma, NSUN4, in collaboration with ALYREF, catalyzes m5C methylation of CDC42 mRNA, thereby stabilizing it and activating the PI3K-AKT pathway, which drives glioma progression [87].